Introduction

53
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of autoimmune origin 54 that affects 0.5-1.0% of the adult population [1, 2] . Treatment of patients with centres 55 on the use of a variety of synthetic disease-modifying antirheumatic drugs (DMARDs) . 56
Methotrexate is the first-line DMARD of choice for the treatment and management of 57 RA, prescribed as monotherapy or in combination with other DMARDs. Although these 58 agents are efficacious for the treatment of RA [3] [4] [5] , clinically meaningful responses are 59 not observed in all patients and a significant proportion remain refractory to treatment. 60 61 A substantial body of literature supports an important role for epigenetic dysregulation, 62 including of DNA methylation, in the pathogenesis of RA [reviewed in [6] [7] [8] . Evidence 63 also suggests that disease modifying agents such as methotrexate may influence DNA 64 methylation [9, 10] . Moreover, methylation status as a potential biomarker associated 65 with response to therapy has been demonstrated in other conditions [11] and proposed 66 for use in RA by several investigators [12, 13] . DNA is methylated through enzymatic 67 conversion of cytosine to methylcytosine; this occurring almost invariably at cytosine-68 phosphate-guanine sites (CpGs). In the context of promoter-associated sites, 69 methylation is associated with transcriptional repression and gene silencing [14] . In RA, 70 alterations to the DNA methylome are apparent in multiple cell types important in the 71 disease process, including peripheral blood-derived mononuclear cells, lymphocytes and 72 joint-derived fibroblasts. Recently, we were the first to define disease-associated 73 8 according to the DAS28-based EULAR response criteria [26] [27] [28] , which evaluate 126 response in patients with RA based on a composite categorization incorporating both 127 change in DAS28 from baseline (∆DAS28) and final absolute DAS28 score. 128
Specifically, these criteria classify response as 'good' (∆DAS28 >1.2, current DAS28 129 ≤3.2), 'moderate' (∆DAS28 >1.2, current DAS28 >3.2, or ∆DAS28 >0.6-1.2, current 130 DAS28 ≤5.1) and 'no' (∆DAS28 ≤0.6, or ∆DAS28 >0.6-1.2, current DAS28 >5.1) [28] . 131
According to these criteria, responders were defined as patients with a 'good' or 132 'moderate' response to treatment, and non-responders as patients with 'no' response to 133
treatment. 134 135
Isolation of T-lymphocytes 136
Fresh peripheral blood samples (35 ml, EDTA) were collected from each patient at 137 baseline, prior to the initiation of treatment. CD3 + T-lymphocytes were isolated from 138 mononuclear cell preparations using positive selection with magnetic microbeads 139 (MACS® Separation System; Miltenyi Biotec). We have previously shown this method 140 to yield high-purity T-lymphocyte populations (mean ≥ 99%) in RA patients [15] . 141 Genomic DNA was extracted using an AllPrep DNA/RNA/miRNA Universal kit 142 (Qiagen) and stored at -20°C prior to use. 143 144 Genome-wide DNA methylation profiling 145 DNA methylation was quantified at >480,000 CpG sites using the 146 HumanMethylation450 BeadChip (Illumina Inc.; hereafter referred to as 'array'). 147
Details of array design and coverage have been described elsewhere [29] . Genomic 148 DNA samples (n = 46) were treated with sodium bisulfite using an EZ DNA 149 9 Methylation Kit (Zymo Research) and subsequently were hybridized to arrays according 150 to manufacturer recommended protocols, as previously described (performed by 151
Hologic Tepnel Pharma Services, Manchester, UK) [30] . All samples passed stringent 152 internal array quality control, including sample-independent (e.g. staining, 153 hybridization) and sample-dependent (e.g. bisulfite conversion) controls. Methylation at 154 individual CpG sites is reported as a β-value ranging from 0 to 1 (unmethylated to fully 155 methylated, respectively) [29] . 156 157
Sodium bisulfite Pyrosequencing 158
Array candidates were independently validated by bisulfite Pyrosequencing using a 159
PyroMark Q24 instrument and analysis software (Qiagen), as we have previously 160 described [15, 30] . Briefly, fresh genomic DNA aliquots were sodium bisulfite-161 converted and amplified using whole genome amplification [30, 31] . Thereafter, 162
Touchdown PCR [32, 33] 
Data analysis 166
Array data (idat files) were processed and analyzed using the Bioconductor package 167
Minfi [34] . We removed from analysis all CpGs with a detection p-value >0.01 in any 168 one or more of the 46 samples and all probes targeting sites on the X and Y 169 chromosomes (a total of 12,295 CpGs). Data were normalized by Subset-quantile 170
Within Array Normalization (SWAN), as described by Maksimovic et al. [35] , and 171 multi-dimensional scaling plots were examined to confirm appropriate adjustment for 172 potential confounding due to batch effects (processing date, array position and slide).
174
To identify methylation differences associated with treatment response, patients were 175 stratified into responders and non-responders. CpGs showing altered methylation 176 between the two groups were identified using the 'dmpFinder' function in Minfi. This 177 function performs an F-test to compare groups and was used with logit-transformed β-178 values (M-values), as recommended by Du et al. [36] . P-values <0.05 were considered 179 statistically significant and, together with a mean β-value difference ≥0.1 between the 180 groups, were used as an initial screening tool to identify sites displaying differential 181 methylation. Two further filtering steps were subsequently applied to identify 182 differentially methylated CpGs as those sites where: 1) at least two-thirds of non-183 responders showed a β-value difference ≥0.1 relative to the responder mean; and 2) at 184 least two-thirds of responders displayed a β-value equal to or in excess of the responder 185 mean. Filtering criteria are summarized in Figure 1 . 
Results
199
Characteristics of the patients 200 Table 1 CpGs, we plotted methylation against treatment response to determine a percentage 234 methylation cut-off that in each case provided the greatest discrimination between 235 patients that responded to treatment and those that did not. Examples of two 236 differentially methylated CpGs are presented in Figure 2 . We also calculated the 237 corresponding sensitivity and specificity for each site to assess the association of 238 methylation status with response. Using this approach, and as shown in Table 2 , four 239 sites were identified with a sensitivity and/or specificity ≥75% for discrimination 240 between responders and non-responders. Most notably, hypermethylation of CpG-2 and 241 hypomethylation of CpG-3 (shown in and non-responder groups included patients receiving methotrexate monotherapy and 305 patients receiving combination therapy, the proportions of which were not significantly 306 different either at baseline or at six-months follow-up (Supplementary Table 2) . 307
Importantly, methylation at two CpGs in combination was strongly associated with 308 treatment response despite the limited variation in treatment regimens, supporting its 309 potential utility as a marker of response at diagnosis in a real-world clinical setting. 310
Furthermore, we purposefully used the EULAR criteria as the response measure in this 311 study as these are universally accepted and encompass both improvement in disease 312 activity over time and end-point disease activity. Reassuringly, the proportion of 313 responders in this study is consistent with previous reports using these criteria [44, 52] . 314
By quantifying methylation at baseline, we are also able to exclude potential 315 confounding associated with DMARDs, including methotrexate, an impact of which on 316 methylation has been suggested by several groups [9, 10, 53, 54] . 317 318 Although our proof-of-concept study is the first of its kind in RA, a limitation of our 319 work was the relatively small number of patients that we were able to recruit. In an 320 attempt to address this, we used a number of sequential filtering steps to identify sites 321 differentially methylated between responders and non-responders to treatment. 322 Furthermore, for the two CpGs comprising the strongest biomarker associated with 323 response, we validated the array data by also quantifying methylation using an 324 independent method (Pyrosequencing). This significantly reduces the risk of type I 325 errors associated with genome-wide approaches. However, we recognise that an 326 important next step will be to confirm our findings and determine the true predictive 327 value of this biomarker in larger, independent patient cohorts. 328
Conclusions
329
In conclusion, we report the identification of a novel DNA methylation combination 330 that is associated with response to treatment with conventional disease-modifying drugs 331 in newly diagnosed patients with RA. Whilst our findings will require verification in 332 larger, independent early RA cohorts, they provide the first evidence to support 333 epigenetic profiling as a novel approach to identifying biomarkers associated with 334 response to DMARD therapy. Ultimately, this has the potential to inform clinical 335 management and patient care, towards the goal of a stratified, personalized medicine 336 approach to treatment. 337
Executive Summary
338
Background 339
• Newly diagnosed patients with rheumatoid arthritis (RA) demonstrate variability of 340 response to treatment with disease-modifying antirheumatic drugs (DMARDs). 341
• To date, no definitive biomarkers associated with response have been identified. 342
• This proof-of-concept study explored whether DNA methylation at first diagnosis is 343 associated with response to treatment with DMARDs in patients with treatment-344 naïve early RA. 345
Patients & Methods 346
• HumanMethylation450 BeadChips were used to quantify genome-wide DNA 347 methylation at diagnosis in T-lymphocytes from 46 treatment-naïve patients with 348 early RA. 349
• Response to DMARD treatment was determined at six months using the DAS28-350 based EULAR response criteria. Sensitivity, specificity and receiver operating 351 characteristic AUC data were used to assess associations of baseline methylation 352 with treatment response. 353
Results
354
• At six-months, the numbers of patients achieving a good/moderate/no response to 355 treatment were 16/19/11 (35/41/24%), respectively. 356
• Array analysis identified 21 CpGs displaying methylation differences between 357 responders and non-responders, of which four statistically significant sites (p adj 358 <0.05, Bonferroni) showed high sensitivity and/or specificity ≥75% for treatment 359 response. 360
• Methylation at two individual sites in combination (cg0301849 and cg14345882) 361 was the strongest factor associated with response, with 80.0% sensitivity and 90.9% 362 specificity (AUC 0.85). 28 of 29 patients with this combination were responders. 363
Conclusions 364
• DNA methylation of a novel CpG combination is associated with treatment response 365 at first diagnosis in early RA patients prior to commencing treatment with 366
DMARDs. 367 Ther. Adv. Musculoskelet. Dis. 7(5), 206-219 (2015) . 
